fashion -WSS

fashion

author：knowledge 2025-09-30 08:00:50 - browse：4973

TRENTON, N.J. — Pharma industry giants including Bristol Myers Squibb, Johnson & Johnson, Novartis, and Novo Nordisk deployed a half-dozen lawyers to a courtroom here Thursday in a bid to dismantle Medicare’s new drug price negotiation program, just hours before President Biden is set to glorify it in his State of the Union.

A federal judge in New Jersey heard an unusual quadruple oral argument in which attorneys for all four drugmakers combined forces to challenge different facets of the Inflation Reduction Act, which in 2022 empowered Medicare to negotiate the prices of a small number of drugs each year beginning in 2026.

Over four hours, the debate spanned most of the substantive issues that pharmaceutical companies and their allies have raised across the country, both in constitutional challenges to the law and in challenges to how Medicare officials have interpreted the law so far. That means the court’s decision in these cases could produce a first substantive test for several of the arguments that haven’t been addressed by courts in other states, where companies like Boehringer Ingelheim, AstraZeneca, and Merck are also suing, separately, over the same law.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： RSV shot was 90% effective at preventing hospitalizations in kids

WSS

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

UnitedHealth quietly bought dozens of outpatient centers

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

explore

fashion

focus

What does generative AI mean for health care? We asked experts

NEJM study link tiny plastics in blood vessels to heart problems

Novavax promises a turnaround & Lilly roils the obesity market

Change Healthcare payments predicted restored March 15

Guidelines to prevent youth baseball injuries need more muscle

UnitedHealth quietly bought dozens of outpatient centers

The high cost of giving birth even with insurance

How to bring more disabled researchers into academia

Novavax promises a turnaround & Lilly roils the obesity market

Amylyx ALS drug failure raises questions and concerns

hotspot

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

With competition flaring, obesity drug hits goal in liver disease study

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

NIH study of ME/CFS points to clear biological hallmarks

UnitedHealth quietly bought dozens of outpatient centers

leisure time

focus

focus

entertainment